Visterra, Inc. Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza With VIS410, a Novel Engineered Human Antibody

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., developer of novel therapeutics to treat major diseases, today announced the presentation of positive data from a preclinical study evaluating the efficacy of the company’s lead product candidate, VIS410, a broadly protective, fully human monoclonal antibody being developed for influenza A infections. Data from preclinical studies were presented today at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. These data were also selected by ICAAC to be included in the public communication highlights for the meeting.

Back to news